IM156, a new drug with original technology of HanAll BioPharma, is to be Introduced at the American Society of Clinical Oncology
IM156, a new drug with original technology of HanAll BioPharma (CEO Park Seung-kook and CEO Yoon Jae-chun), is to be Introduced at the American Society of Clinical Oncology (ASCO) held in Chicago for five days starting June 1.
IM156 is a new anticancer drug that is under phase 1 clinical trial at ImmunoMet, a spun-off company, after completion of preclinical trial at HanAll BioPharma, and it showed the treatment efficacy for △ glioblastoma △ gastric cancer △ lymphoma.
The new drug has a mechanism to prevent the growth of cancer by inhibiting energy metabolism of tumors. Phase 1 clinical trial of the drug will be completed by the end of this year and phase 2 clinical trial will begin next year.
An official of ImmunoMet said, “IM156 is a leading drug candidate of ImmunoMet, a company derived from HanAll BioPharma, and we expect that it will give hope to patients suffering from intractable cancers as a medicine that can treat cancer cells in new ways.” “ImmunoMet’s growth will also be with IM156,” he added.
HanAll BioPharma owns about 11% of ImmunoMet’s shares as of the end of last year. HanAll transferred the technology of IM156, an anticancer drug, and singed a profit-sharing contract on the drug with ImmunoMet. Therefore, they will share revenue made from the drug when the drug is commercialized or licensed out.
Meanwhile, ASCO was established in 1964 as the world's largest cancer-related event, and it is consisted of more than 40,000 members who are physicians.